Experiences with
Tyrosine762 public posts
BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL
Bruton’s tyrosine kinase (BTK) degraders are a new class of medications that have potential to be effective in this scenario. This review describes the mechanism of action of BTK degraders, and their pre-clinical and clinical development to date, including emerging clinical trial data.
Want to take advantage of all our features? Just log in!
or
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
randomized trial with 238 patients, with my emphasis; https://www.medpagetoday.com/meetingcoverage/ashhematology/113337
[i]Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton's tyrosine
Improving Treatment Options for Patients with Double Refractory CLL - patients who progressed after treatment with both cBTKis and BCL2i
Approvals of multiple covalent Bruton's tyrosine kinas inhibitors (cBTKis) as well as the B-cell lymphoma-2 inhibitor (BCL2i) venetoclax targeting these pathways have revolutionized the treatment of CLL and small lymphocytic lymphoma (SLL).
LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase. Phase 1 trial results.
Rocbrutinib is a new drug offering hope to patients with what are known as gatekeeper mutations that confer resistance to Pirtobrutinib. This BTKi is unique in being both a covalent and non covalent inhibitor of BTK.
Patients with gatekeeper mutations have poor outcomes and short survival and demonstrate